ATE358136T1 - Prionen-bindende peptidsequenzen - Google Patents

Prionen-bindende peptidsequenzen

Info

Publication number
ATE358136T1
ATE358136T1 AT02779505T AT02779505T ATE358136T1 AT E358136 T1 ATE358136 T1 AT E358136T1 AT 02779505 T AT02779505 T AT 02779505T AT 02779505 T AT02779505 T AT 02779505T AT E358136 T1 ATE358136 T1 AT E358136T1
Authority
AT
Austria
Prior art keywords
peptide sequences
binding peptide
prion binding
prp
prion protein
Prior art date
Application number
AT02779505T
Other languages
English (en)
Inventor
Theodoros Sklaviadis
Cindy Panagiotides
John Paspaltsis
Basil Karageorgis
Original Assignee
Ct For Res And Technology Hell
Theodoros Sklaviadis
Cindy Panagiotides
John Paspaltsis
Basil Karageorgis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct For Res And Technology Hell, Theodoros Sklaviadis, Cindy Panagiotides, John Paspaltsis, Basil Karageorgis filed Critical Ct For Res And Technology Hell
Application granted granted Critical
Publication of ATE358136T1 publication Critical patent/ATE358136T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047Simultaneous synthesis of different peptide species; Peptide libraries
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1019Tetrapeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02779505T 2002-10-23 2002-10-23 Prionen-bindende peptidsequenzen ATE358136T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2002/011868 WO2004037854A1 (en) 2002-10-23 2002-10-23 Prion protein-binding peptide sequences

Publications (1)

Publication Number Publication Date
ATE358136T1 true ATE358136T1 (de) 2007-04-15

Family

ID=32116206

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02779505T ATE358136T1 (de) 2002-10-23 2002-10-23 Prionen-bindende peptidsequenzen

Country Status (8)

Country Link
EP (1) EP1554305B1 (de)
AT (1) ATE358136T1 (de)
AU (1) AU2002342850A1 (de)
DE (1) DE60219215T2 (de)
DK (1) DK1554305T3 (de)
ES (1) ES2283608T3 (de)
PT (1) PT1554305E (de)
WO (1) WO2004037854A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ545385A (en) 2003-08-13 2010-12-24 Novartis Vaccines & Diagnostic Prion-specific peptide reagents
CN101356186A (zh) 2005-09-09 2009-01-28 诺华有限公司 朊病毒-特异性拟肽试剂
DK2049664T3 (da) 2006-08-11 2012-01-02 Prosensa Technologies Bv Enkeltstrengede oligonukleotider, som er komplementære til repetitive elementer, til behandling af med DNA-repetitiv-ustabilitet associerede lidelser
AU2008273096B2 (en) * 2007-07-12 2013-05-02 Academisch Ziekenhuis Leiden Molecules for targeting compounds to various selected organs or tissues
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
CN101896186A (zh) 2007-10-26 2010-11-24 莱顿教学医院 对抗肌肉病症的方式和方法
EP2119783A1 (de) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
CA2759899A1 (en) 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
BR112014018427B1 (pt) 2012-01-27 2021-11-03 Biomarin Technologies B.V. Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU731291B2 (en) * 1997-06-02 2001-03-29 Regents Of The University Of California, The Prion protein modulator factor (PPMF) and prion resistant animals
GB9823835D0 (en) * 1998-10-30 1998-12-23 Univ London Component for vaccine
US6399575B1 (en) * 1998-11-10 2002-06-04 Auburn University Methods and compositions for targeting compounds to the central nervous system
WO2001005968A1 (en) * 1999-06-21 2001-01-25 Inkine Pharmaceutical Company, Inc. Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor
US6743893B2 (en) * 2000-11-30 2004-06-01 The Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
ATE385811T1 (de) * 2000-12-19 2008-03-15 Palatin Technologies Inc Identifizierung zielgerichteter faltungsstellen in peptiden und proteinen

Also Published As

Publication number Publication date
EP1554305A1 (de) 2005-07-20
AU2002342850A1 (en) 2004-05-13
DE60219215T2 (de) 2008-01-03
PT1554305E (pt) 2007-05-31
DE60219215D1 (de) 2007-05-10
WO2004037854A1 (en) 2004-05-06
AU2002342850A8 (en) 2004-05-13
DK1554305T3 (da) 2007-04-23
ES2283608T3 (es) 2007-11-01
EP1554305B1 (de) 2007-03-28

Similar Documents

Publication Publication Date Title
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
GB2433936A (en) Therapeutic peptides comprising sequences derived from CDR2 or CDR3 of trem-1 and uses thereof to inhibit sepsis
DE602004006433D1 (de) Pyrrol-substituierte indole als inhibitoren von pai-1
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
HRP20070196T3 (hr) Postupak za pročišćavanje il-18 vezivnog proteina
ATE267830T1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
NO20090624L (no) Forbindelser som modulerer CB2 receptoren
WO2006023844A3 (en) Compositions and methods comprising proteinase activated receptor antagonists
GEP20115324B (en) Tweak binding antibodies
BRPI0517973A (pt) método para purificar o fsh
PL1689378T3 (pl) Nowe zastosowanie związków peptydowych do leczenia ośrodkowego bólu neuropatycznego
NO20083050L (no) Forbindelser og fremgangsmater for hemming av interaksjon av Bcl-proteiner med bindingspartnere
NO20053111L (no) Peptider som inhiberer angiogenese, cellemigrering, celleinvasjon og celleproliferering.
DK1554305T3 (da) Prionprotein-bindende peptidsekvenser
DE50013435D1 (de) Peptide gegen dcm hervorrufende autoantikörper
TW200724140A (en) Hydantoin compounds
DE60207043D1 (de) Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese
MX2008000230A (es) Proteinas de enlace il-6.
EA200801180A1 (ru) Селективные пептидные агонисты рецептора vpac2
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
UA87117C2 (ru) Применение пептидных соединений для лечения центральной невропатической боли
ATE546154T1 (de) Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung
CY1109904T1 (el) Προαγωγεας της il-18bp, η παρασκευη και χρηση του

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1554305

Country of ref document: EP

REN Ceased due to non-payment of the annual fee